CAR T-Cell therapy sends multiple myeloma into lasting remission … – Science Daily
FierceBiotech |
CAR T-Cell therapy sends multiple myeloma into lasting remission …
Science Daily In an early clinical trial, 33 out of 35 (94 percent) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy — chimeric … CAR T-cell therapy shows promise for patients with myeloma ASCO dark horse Nanjing Legend Biotech shines with promising CAR–T data Bluebird is pretty chirpy about its anti-BCMA CAR-T therapy results … |
